A PHASE 1B DOSE-RANGING STUDY OF 4 WEEKS OF PEG-INTERFERON (IFN) LAMBDA (PEG-RIL-29) IN COMBINATION WITH RIBAVIRIN (RBV) IN PATIENTS WITH CHRONIC GENOTYPE 1 HEPATITIS C VIRUS (HCV) INFECTION

被引：0
|
作者：
Muir, Andrew [1 ]
Shiffman, Mitchell L. [2 ]
Zaman, Atif [3 ]
Yoffe, Boris [4 ]
Lopez-Talavera, Juan Carlos [5 ]
Souza, Sherri [6 ]
Hausman, Diana F. [6 ]
Lawitz, Eric [7 ]
机构：
[1] Duke Univ, Durham, NC USA
[2] VCU Med Ctr, Richmond, VA USA
[3] Oregon Hlth & Sci Univ, Portland, OR USA
[4] Baylor Coll Med, Houston, TX 77030 USA
[5] Bristol Myers Squibb Co, New York, NY 10154 USA
[6] ZymoGenetics Inc, Seattle, WA USA
[7] Alamo Med Res, San Antonio, TX USA
来源：
HEPATOLOGY | 2009年 / 50卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1591
引用
收藏
页码：1039A / 1040A
页数：2
相关论文
共 50 条
  • [21] Assessment of Hepatitis C Virus Protein Sequences with Regard to Interferon/Ribavirin Combination Therapy Response in Patients with HCV Genotype 1b
    Glisic, Sanja
    Veljkovic, Nevena
    Cupic, Snezana Jovanovic
    Vasiljevic, Nada
    Prljic, Jelena
    Gemovic, Branislava
    Perovic, Vladimir
    Veljkovic, Veljko
    PROTEIN JOURNAL, 2012, 31 (02): : 129 - 136
  • [22] INTERLEUKIN-28B GENETIC VARIANTS AND PERIPHERAL BLOOD INTERFERON RECEPTOR 2 IN PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1B AND HIGH VIRAL LOADS TREATED WITH PEG-INTERFERON AND RIBAVIRIN
    Shinohara, Mie
    Ishii, Koji
    Kogame, Michio
    Kanayama, Kaori
    Shinohara, Masao
    Nagai, Hidenari
    Watanabe, Manabu
    Morita, Toshisuke
    Sano, Masanari
    Sumino, Yasukiyo
    HEPATOLOGY, 2011, 54 : 828A - 828A
  • [23] Assessment of Hepatitis C Virus Protein Sequences with Regard to Interferon/Ribavirin Combination Therapy Response in Patients with HCV Genotype 1b
    Sanja Glisic
    Nevena Veljkovic
    Snezana Jovanovic Cupic
    Nada Vasiljevic
    Jelena Prljic
    Branislava Gemovic
    Vladimir Perovic
    Veljko Veljkovic
    The Protein Journal, 2012, 31 : 129 - 136
  • [24] Treatment with Peg-Interferon alfa-2b (PEG-IFN) plus ribavirin compared to interferon alfa-2b (INF alfa-2b)plus ribavirin on subjects with chronic hepatitis C infected with HCV genotype 4.
    Esmat, G
    Abouzied, AM
    Abdel-Aziz, F
    Mohamed, MK
    Abdel-Hamid, M
    El Raziky, MS
    Ismail, SA
    Zalata, KR
    Mikhail, NN
    Fix, A
    Strickland, T
    Sjogren, MH
    HEPATOLOGY, 2002, 36 (04) : 364A - 364A
  • [25] Paradoxes in Novel Hepatitis C Therapies: Is Combination of Sofosbuvir and Ribavirin Without Interferon Effective in Genotype 1b Chronic HCV Patients?
    Karagoz, Ergenekon
    Turhan, Vedat
    Ulcay, Asim
    Tanoglu, Alpaslan
    Erdem, Hakan
    VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL, 2015, 21 (02): : 62 - 64
  • [26] PEG-IFN-λ: ANTIVIRAL ACTIVITY AND SAFETY PROFILE IN A 4-WEEK PHASE 1B STUDY IN RELAPSED GENOTYPE 1 HEPATITIS C INFECTION
    Shiffman, M.
    Lawitz, E.
    Zaman, A.
    Vierling, J.
    Yoffe, B.
    Freeman, J.
    Gray, T.
    Hausman, D.
    Muir, A.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S237 - S237
  • [27] KIR2DL2/C1 is a Risk Factor for Chronic Infection and Associated with Non-response to PEG-IFN and RBV Combination Therapy in Hepatitis C Virus Genotype 1b Patients in China
    Song Hu
    Fahu Yuan
    Lingyan Feng
    Fang Zheng
    Feili Gong
    Hanju Huang
    Binlian Sun
    Virologica Sinica, 2018, 33 (04) : 369 - 372
  • [28] KIR2DL2/C1 is a Risk Factor for Chronic Infection and Associated with Non-response to PEG-IFN and RBV Combination Therapy in Hepatitis C Virus Genotype 1b Patients in China
    Song Hu
    Fahu Yuan
    Lingyan Feng
    Fang Zheng
    Feili Gong
    Hanju Huang
    Binlian Sun
    Virologica Sinica, 2018, (04) : 369 - 372
  • [29] KIR2DL2/C1 is a Risk Factor for Chronic Infection and Associated with Non-response to PEG-IFN and RBV Combination Therapy in Hepatitis C Virus Genotype 1b Patients in China
    Hu, Song
    Yuan, Fahu
    Feng, Lingyan
    Zheng, Fang
    Gong, Feili
    Huang, Hanju
    Sun, Binlian
    VIROLOGICA SINICA, 2018, 33 (04) : 369 - 372
  • [30] Fluvastatin does not exhibit antiviral effect on PEG-IFN/Ribavirin/Telaprevir therapy for genotype 1b chronic hepatitis C
    Itokawa, Norio
    Atsukawa, Masanori
    Shimada, Noritomo
    Nakagawa, Ai
    Kondo, Chisa
    Matsushita, Yoko
    Fukuda, Takeshi
    Narahara, Yoshiyuki
    Nakatsuka, Katsuhisa
    Iwakiri, Katsuhiko
    Sakamoto, Choitsu
    HEPATOLOGY, 2013, 58 : 1119A - 1119A
12345